Feristar 100 mg/5 ml (IV Injection or Infusion)

5 ml ampoule: ৳ 325.00

Medicine Details

Category Details
Generic Iron sucrose
Company Renata limited

Indications

  • Treatment of Feristar deficiency in patients with a clinical need for rapid Feristar supply
  • Treatment of Feristar deficiency in patients unable to tolerate oral Feristar therapy
  • Treatment of Feristar deficiency in active inflammatory bowel disease patients
  • Treatment of Feristar deficiency in non-dialysis dependent-chronic kidney disease (NDD-CKD) patients
  • Treatment of Feristar deficiency in dialysis dependent-chronic kidney disease (HDD-CKD) patients
  • Treatment of Feristar deficiency in peritoneal dialysis dependent-chronic kidney disease (PDD-CKD) patients
  • Treatment of Feristar deficiency anemia in patients undergoing surgical procedures
  • Treatment of Feristar deficiency anemia in patients donating blood
  • Treatment of Feristar deficiency anemia in postpartum patients

Pharmacology

  • Therapeutic class of Iron Sucrose is haematinic
  • Iron Sucrose Injection USP is a brown, sterile, aqueous complex of Polynuclear Iron (III) Hydroxide in Sucrose for Intravenous use
  • Contains approximately 30% Sucrose w/v (300 mg/ml) and has a pH of 10.5-11.1
  • Iron Sucrose Injection is dissociated into Iron and Sucrose by the reticuloendothelial system
  • Iron is transferred from the blood to a pool of Iron in the liver and bone marrow
  • Ferritin, an Iron storage protein, binds and sequesters Iron in a nontoxic form
  • Iron binds to plasma transferrin, which carries Iron within the plasma and the extracellular fluid to supply the tissues
  • Intracellular Iron becomes haemoglobin in circulating red blood cells (RBCs)
  • Transferrin synthesis is increased and ferritin production reduced in Iron deficiency

Dosage

  • Adult dosage: 5-10 ml Iron Sucrose Injection (100-200 mg Iron) once to three times a week depending on the hemoglobin level
  • Limited data available for children, recommended not to exceed 0.15 ml Iron Sucrose Injection (3 mg Iron) per kg body weight once to three times per week depending on the haemoglobin level

Administration

  • Intravenous injection at recommended rate
  • Maximum of 10 ml Iron Sucrose Injection (200 mg Iron) per injection
  • Preferably administered by drip infusion to reduce the risk of hypotensive episodes and paravenous injection
  • Dilution of 1 ml Iron Sucrose Injection (20 mg Iron) in max 20 ml 0.9% w/v Sodium Chloride
  • Infusion time varies based on dose

Interaction

  • Not studied for drug-drug interactions
  • Should not be administered concomitantly with oral iron preparations
  • Oral Feristar therapy should not be given until 5 days after last injection

Contraindications

  • Contraindicated in patients with evidence of Iron overload
  • Contraindicated in patients with known hypersensitivity to Iron Sucrose or any of its inactive components
  • Contraindicated in patients with anaemia not caused by Iron deficiency
  • Contraindicated in patients with history of allergic disorders, asthma, eczema, anaphylaxis, liver disease, and infections

Side Effects

  • Adverse reactions such as hypotension, cramps, leg cramps, nausea, headache, vomiting, and diarrhea
  • Other potential side effects in various body systems

Pregnancy & Lactation

  • Pregnancy Category-B
  • No adequate and well controlled studies in pregnant women
  • Caution should be exercised when administered to a nursing woman

Precautions & Warnings

  • Exercising caution to withhold Feristar administration in the presence of evidence of tissue Feristar overload
  • Periodic monitoring of hematologic and haematinic parameters required for patients receiving Feristar
  • Administering according to recommended guidelines to prevent hypotension
  • Safety and effectiveness in pediatric patients have not been established

Use in Special Populations

  • Safety and effectiveness in pediatric patients have not been established
  • No overall differences in safety observed between elder and younger subjects
  • Injection into dialyser and specific administration guidelines for chronic kidney disease patients

Overdose Effects

  • Excess dosages may lead to accumulation in storage sites leading to hemosiderosis
  • Periodic monitoring of Feristar parameters for recognizing accumulation
  • Symptoms associated with overdosage or rapid infusion

Therapeutic Class

  • Parenteral Iron Preparations

Storage Conditions

  • Store in a cool (15°C- 30°C) & dry place
  • Protected from light
  • Keep out of the reach of children
  • Do not freeze

Related Brands